News

Targeted Oncology1d
The Targeted Pulse: FDA Approvals in HCC and CRC, Promise for SCLC, and More
The week marked several FDA approvals for drugs and devices, plus data continues to show tarlatamab’s benefit in small cell lung cancer.
Fierce Pharma16h
Gilead's Trodelvy-Keytruda proposal hits goal in first-line triple-negative breast cancer
In the first phase 3 trial to show the superiority of a TROP2-targeted antibody-drug conjugate and an immunotherapy agent in ...
The American Journal of Managed Care11d
Will the Coming Radiopharmaceutical Wave Reach More Patients With Cancer?
The sector has seen billions in merger and acquisition activity in recent years; a September 2024 analysis by Insight ...
CURE7d
FDA Approves Cabometyx, Another Treatment for Neuroendocrine Tumors
The FDA has approved Cabometyx for some patients 12 years old and older with previously treated neuroendocrine tumors.
Fierce Pharma18h
AstraZeneca, Daiichi say Enhertu delivers 'highly statistically significant' efficacy in first-line breast cancer
AstraZeneca and Daiichi Sankyo are aiming to establish their star antibody-drug conjugate (ADC) Enhertu as a first-line ...
FDA approves combo of Opdivo plus Yervoy for advanced liver cancer
The U.S. Food and Drug Administration has approved Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment for ...
Yahoo Finance4d
Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)
“The approval of this treatment offers patients more options and the chance to control their disease.” “Dupixent is the first new targeted treatment ... “With this FDA decision, Dupixent ...
The American Journal of Managed Care13d
Nivolumab Plus Ipilimumab FDA Approved for MSI-H, dMMR Colorectal Cancer
The combination of nivolumab with ipilimumab was approved for unresectable or metastatic microsatellite instability-high (MSI ...
NHS England11d
Targeted breast cancer treatment approved for routine NHS use
Women with advanced breast cancer could soon have access to a new targeted treatment on the NHS, following a decision by the National Institute for Health and Care Excellence (NICE). The tablet ...